ClinicalTrials.gg
CompletedNCT04550832DECODEUpdated Sep 16, 2025Results posted

PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)

A Phase 2 interventional study of Delpazolid and Bedaquiline, Delamanid, Moxifloxacin in Infections and Infestations and Pulmonary Tuberculosis, sponsored by LigaChem Biosciences, Inc.. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-16.

Primary conditionTuberculosis, PulmonaryRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Tuberculosis, Pulmonary
Why
  1. The study's listed conditions name Tuberculosis, Pulmonary, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by LigaChem Biosciences, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Tuberculosis, Pulmonary with a site in Tanzania — 4 open to participants now, 6 under way, none of them phase 3. Tuberculosis, Pulmonary · Tanzania.

Enrollment
14th of 15
76 · median 365
Started
2021
with 3 others
Phase 2
12 of 17
4 open now
Registered
9th of 17
by date
Lead sponsor
1 of 17
LigaChem Biosciences, Inc.

Among the 17 studies in Tuberculosis, Pulmonary with a site in Tanzania, this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2021, is one of 12 in phase 2, and was the 9th registered.

Tuberculosis, Pulmonary

320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

4 of the 17 studies in Tuberculosis, Pulmonary with a site in Tanzania are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Tanzania have not opened yet or have stopped. Only those recruiting at a site in Tanzania →

Who these studies take

Of the 47 Tuberculosis, Pulmonary studies recruiting now, 22 (47%) set no upper age limit and 21 (45%) stop at 75 or younger; 12 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Tuberculosis, Pulmonary with a site in Tanzania, or all of them as a file.
02

Study summary

This trial is to describe the safety, tolerability and exposure-toxicity relationship of Depazolid given over 16 weeks, in combination with standard-dose Bedaquiline, Delamanid and Moxifloxacin, compared to standard-dose Bedaquiline, Delamanid and Moxifloxacin alone

Read the detailed description

This will be an open label Phase IIb dose-finding, randomized, controlled study with a duration of 16 weeks of experimental therapy of Delpazolid(DZD) - Bedaquiline/Delamanid/ Moxifloxacin (BDM) in adult patients with newly diagnosed, smear positive, uncomplicated, drug sensitive pulmonary tuberculosis (TB) to evaluate the safety, efficacy, tolerability, pharmacokinetics and exposure/response-relationship of different doses of delpazolid in combination with bedaquiline, delamanid and moxifloxacin.

Participants will be randomized to one of five arms containing BDM standard dose with different doses of DZD.

03

Conditions studied

  • Infections and Infestations
  • Pulmonary Tuberculosis

Browse trials for

Keywords

  • drug-sensitive TB
04

In context

Tuberculosis, Pulmonary Reclassified

320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.

This study's enrollment of 76 is below the median of 147 across 228 interventional studies indexed under Tuberculosis, Pulmonary.

Browse Tuberculosis, Pulmonary studies →

Lead sponsor

LigaChem Biosciences, Inc. is the lead sponsor of 15 studies on the registry; 3 are open to participants now.

Compared within Tuberculosis, Pulmonary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written, prior to all trial-related procedures including testing.
  2. Male or female, aged between 18 and 65 years, inclusive.
  3. Body weight between 40 and 90 kg, inclusive.
  4. Newly diagnosed, previously untreated, drug susceptible pulmonary TB: presence of MTB complex and rapid molecular tests result confirming susceptibility to RIF and INH such as GeneXpert and/or HAIN MTBDR plus.
  5. A chest X-ray (no older than 2 weeks) which, in the opinion of the Investigator, is consistent with TB.
  6. Sputum positive on microscopy from concentrated sputum for acid-fast bacilli on at least one sputum sample (at least 1+ on the IUATLD/WHO scale).
  7. The participant is willing to forgo consumption of foods high in tyramine for the period of taking study medication (See Appendix, section 20.2, page 92).
  8. The participant is either unable to conceive/father children AND/OR his/her partner is unable to conceive/father children AND/OR they will consent to be using effective methods of when engaging in heterosexual intercourse, as defined below:

    a. Non-: i. Female participant/sexual partner of male participant: Bilateral oophorectomy, and/or hysterectomy or bilateral tubal ligation more than 12 months ago and/or has been with a history of no menses for at least 12 consecutive months ii. Male participant/sexual partner of female participant: Vasectomised or has had a bilateral orchidectomy minimally three months prior to screening iii. Male participants having a pregnant female partner or a male sexual partner: At least one barrier method has to be used in this case. b. Effective contraception methods: i. Female participants: Two methods, including methods that the patient's sexual partner(s) use. At least one must be a barrier method. Contraception must be practised for at least until 12 weeks after the last dose of DZD. ii. Male participants: Two methods, including methods that the patient's female sexual partner(s) use. At least one must be a barrier method. Effective contraception must be ensured for at least 16 weeks after the last dose of DZD.

Note: hormone-based contraception alone may not be reliable when taking RIF during continuation phase; therefore, hormone-based contraceptives alone cannot be used by female participants/female partners of male participants to prevent pregnancy.

Exclusion criteria

Exclusion Criteria:

  1. Circumstances that raise doubt about free, unconstrained consent to study participation (e.g. prisoner or mentally handicapped person)
  2. Poor general condition where delay in treatment cannot be tolerated or death within four months is likely.
  3. Poor social condition which would make it unlikely that the patient would be able to complete follow-up
  4. The patient is pregnant or breast-feeding.
  5. The patient is infected with with a \<220 cells/mm3. If >220 cells/mm3, patients will be included only if any of the following is applicable:

    • The patient is antiretroviral (ARV) naïve and able to postpone commencing HIV treatment for 2 months after the trial has started and then restrict regimens to those containing dolutegravir (see section 12.6.2 on ARVs) or The patient is ARV experienced (has been on ARV´s a minimum of 5 months) and able to switch to a dolutegravir-based regimen.
    • The patient is treated with nucleosidic reverse transcriptase inhibitors (are permitted as concomitant medication).
    • The patient is treated with protease inhibitors as part of antiretroviral treatment regimens, which will be stopped at least 3 days before the start of study treatment (WK01, day1) for a patient to be eligible.
    • The patient is treated with Efavirenz as part of antiretroviral treatment regimens which would have to be stopped 14 days before the start of study treatment (WK00, Day 01) for a patient to be eligible.
  6. The patient has a known intolerance to any of the study drugs or concomitant disorders or conditions for which study drugs or standard TB treatment are
  7. The patient has a history of, or current evidence of cardiovascular metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, , or any other condition that will influence treatment response, study adherence or survival in the judgement of the investigator, especially:

    1. Neuropathy, or significant psychiatric disorder like depression or schizophrenia; especially if treatment for those has ever been required or is anticipated to be required
    2. Clinically significant evidence of extra-pulmonary TB (e.g. miliary TB, TB meningitis, but not limited lymph node involvement)
    3. Serious lung conditions other than TB, or significant respiratory impairment in the discretion of the investigator
    4. Any diabetes mellitus
    5. Cardiovascular disease such as myocardial infarction, heart failure, coronary heart disease, arrhythmia, tachyarrhythmia, or pulmonary hypertension
    6. Arterial hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure of ≥90 mmHg on two occasions during screening).
    7. Long syndrome or family history of long QT syndrome or sudden death of unknown or cardiac-related cause
    8. Alcohol or other drug abuse that is sufficient to significantly compromise the safety or cooperation of the patient, that includes substances prohibited by the protocol or has led to significant organ damage at the discretion of the investigator.
  8. Any of the following laboratory findings at screening:

    1. Serum amino aspartate transferase () and/or alanine aminotransferase (ALT) >3x the (ULN),
    2. Serum alkaline phosphatase or y-glutamyl transferase > 2.5x the ULN,
    3. Serum total level >1.5x the ULN
    4. Estimated (eCrCl; using the Cockroft and Gault formula [57] lower than 30 ml/min
    5. Serum albumin \< 2.8 mg/dl
    6. level \<7.0 g/dl
    7. count \<50,000/mm3
    8. Serum potassium below the lower level of normal for the laboratory
    9. Blood glucose at screening of less than 70mg/dL (3.9mmol/L)
  9. findings in the screening ECG: (one or more):

    1. QTcF of >0.450 s
    2. Atrioventricular (AV) block with PR interval > 0.20 s,
    3. QRS complex > 120 milliseconds
    4. Any other changes in the ECG that are clinically relevant as per discretion of the investigator
  10. Restricted medication:

    1. Treatment with any other drug within 1 month prior to enrolment or enrolment into other clinical (intervention) trials during participation.
    2. Previous anti-TB treatment with drugs active against MTB within the last 3 months prior to screening.
    3. Unable or unwilling to abide by the requirements regarding restricted medication or have taken restricted medication as described under section 12.6, page 58. Restricted medication includes the following drug classes:

      • Anti-TB drugs other than study drugs
      • Medication that lowers the threshold for epileptic seizures
      • Medication that prolongs the QTc interval
      • Drugs that affect monoaminooxidase or serotonin metabolism
      • CYP 450 inhibitors or inducers, including grapefruit containing foods / beverages and St. John's Wort
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Active comparator
    Arm1(D0)

    Participants receive the following medication for the duration of 16weeks together with food. * Delpazolid : Will not administered * Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week. * Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg. * Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily

    Drug: Bedaquiline, Delamanid, Moxifloxacin

  • Experimental
    Arm2(D400)

    Participants receive the following medication for the duration of 16weeks together with food. * Delpazolid : Will be dosed 400 mg orally once daily * Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week. * Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg. * Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily

    Drug: Delpazolid · Drug: Bedaquiline, Delamanid, Moxifloxacin

  • Experimental
    Arm3(D800-OD)

    Participants receive the following medication for the duration of 16weeks together with food. * Delpazolid : Will be dosed 800 mg orally once daily * Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week. * Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg. * Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily

    Drug: Delpazolid · Drug: Bedaquiline, Delamanid, Moxifloxacin

  • Experimental
    Arm4(D1200)

    Participants receive the following medication for the duration of 16weeks together with food. * Delpazolid : Will be dosed 1200 mg orally once daily * Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week. * Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg. * Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily

    Drug: Delpazolid · Drug: Bedaquiline, Delamanid, Moxifloxacin

  • Experimental
    Arm5(D800-BD)

    Participants receive the following medication for the duration of 16weeks together with food. * Delpazolid : Will be dosed 800 mg orally twice daily * Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week. * Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg. * Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily

    Drug: Delpazolid · Drug: Bedaquiline, Delamanid, Moxifloxacin

Interventions

07

What researchers measure

Primary outcomes

  1. Safety Outcome : Proportion of Patients Experiencing Adverse Event

    Participants with ≥ 1 TEAE, by severity, related Adverse events: possibly, probably, or definitely related to study drugs

    Time frame: week0 - week52

  2. Efficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_AUC0-24

    The efficacy of DZD was evaluated by measuring the change in mycobacterial load over time on treatment as quantified by TTP (Time to positive) in BD MGIT960® liquid culture described by non linear mixed effects methodology. A population PK model was developed using NONMEM version 7.4.1. DZD PK is well-described by a two-compartment model with first-order absorption, first-order elimination and a proportional residual error. The final model included allometric scaling based on FFM.

    Time frame: Week 0 - Week 16

  3. Efficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_Cmax

    The efficacy of DZD was evaluated by measuring the change in mycobacterial load over time on treatment as quantified by TTP (Time to positive) in BD MGIT960® liquid culture described by non linear mixed effects methodology. A population PK model was developed using NONMEM version 7.4.1. DZD PK is well-described by a two-compartment model with first-order absorption, first-order elimination and a proportional residual error. The final model included allometric scaling based on FFM.

    Time frame: Week 0 - Week 16

  4. Efficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_Cmin

    The efficacy of DZD was evaluated by measuring the change in mycobacterial load over time on treatment as quantified by TTP (Time to positive) in BD MGIT960® liquid culture described by non linear mixed effects methodology. A population PK model was developed using NONMEM version 7.4.1. DZD PK is well-described by a two-compartment model with first-order absorption, first-order elimination and a proportional residual error. The final model included allometric scaling based on FFM.

    Time frame: Week 0 - Week 16

Secondary outcomes

  1. Efficacy Outcome: BD MGIT960® Liquid Media Culture Results

    Summary of Changes in Mycobacterial Load Over Time on Treatment as Quantified by Time to Positivity in BD MGIT960® Liquid Media - Intent to Treat Population Sputum samples were collected for BD MGIT960® Liquid Media culture at all time points during the treatment and follow-up phases, and this table shows culture results, which are reported as: Positive, Negative, Contaminated, Missing. Note: Contaminated cultures are shown as contaminated for the purpose of the overall result but are counted as missing for calculating summary statistics. The data recorded as 'Positive for MTB Complex with Contamination' are included as 'Positive' for MGIT result. However, the data from mean and median calculations for TTP (Time to positive) due to contamination.

    Time frame: Week 0 - Week 16

  2. Efficacy Outcome: Changes in Mycobacterial Load Over Time on Treatment as Quantified by Time to Positivity in BD MGIT960® Liquid Media

    The efficacy of DZD was evaluated by measuring the change in mycobacterial load over time on treatment as quantified by time to positivity (TTP) in BD MGIT 960® liquid culture described by nonlinear mixed-effects methodology. Sputum samples were collected for BD MGIT960® Liquid Media culture at all time points during the treatment and follow-up phases, and this table shows TTP results.

    Time frame: Week 0 - Week 16

  3. Efficacy Outcome: Loewenstein-Jensen Solid Media Culture Results

    Summary of Changes in Mycobacterial Load Over Time on Treatment as Quantified by Time to Culture Conversion in Loewenstein-Jensen Solid Media - Intent-to-Treat Population Sputum samples were collected for Loewenstein-Jensen Solid Media culture at at Week 0, Week 8, Week 12, Week 6 during the treatment and follow-up phases, and this table shows culture results, which are reported as: Positive, Negative, Contaminated, Missing.

    Time frame: Week 0 - Week 16

  4. Efficacy Outcome: The Proportion Converted by Day Corresponding to End of Each Week

    Culture conversion was defined as 2 negative cultures without an intervening positive culture. Time was measured as time on treatment until the first negative culture (up to Week 16 Visit). 'Converted by Week x' shows proportion converted by day corresponding to end of each week, e.g., Week 2 = Day 14.

    Time frame: Week 0 - Week 16

  5. Efficacy Outcome: Time to Culture Conversion

    Time to culture conversion was defined as 2 negative cultures without an intervening positive culture. Time was measured as time on treatment until the first negative culture (up to Week 16 Visit).

    Time frame: Week 0 - Week 16

  6. Efficacy Outcome : Relapse or Reinfection

    A participant was positive for relapse or reinfection if they converted to culture negative by Week 8 and had 2 consecutive positive cultures after Week 16 of randomization, without an intervening negative.

    Time frame: Week0 - Week52

08

Results

Posted Oct 28, 2024

Participant flow

Participant flow — Overall Study
MilestoneArm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)
Started1515151615
Received ≥ 1 dose of study drug1515151615
Completed1515131614
Not completed00201
Withdrew: Adverse event00201

Outcome measures

PrimarySafety Outcome : Proportion of Patients Experiencing Adverse Event

Participants with ≥ 1 TEAE, by severity, related Adverse events: possibly, probably, or definitely related to study drugs

Time frame:
week0 - week52
Reported as:
Count of participants · Participants
Safety Outcome : Proportion of Patients Experiencing Adverse Event
ParticipantsArm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)
TEAE (total)87769
Grade 1 (mild)43001
Grade 2 (moderate)44557
Grade 3 (severe)00113
Grade 4 (life-threatening)00200
Unrelated53636
Unlikely related01111
Possibly related21014
Probably related01110
Definitely related11000
SAE- Grade 3 (severe)00002
SAE-Grade 4 (life-threatening)00100
DZD-unrelated SAEs00100
DZD-related SAEs00002
PrimaryEfficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_AUC0-24

The efficacy of DZD was evaluated by measuring the change in mycobacterial load over time on treatment as quantified by TTP (Time to positive) in BD MGIT960® liquid culture described by non linear mixed effects methodology. A population PK model was developed using NONMEM version 7.4.1. DZD PK is well-described by a two-compartment model with first-order absorption, first-order elimination and a proportional residual error. The final model included allometric scaling based on FFM.

Time frame:
Week 0 - Week 16
Reported as:
Median · mg/L*h
Efficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_AUC0-24
mg/L*hArm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)
Efficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_AUC0-24NA (NA to NA)10.1 (6.86 to 20.4)28.6 (15.1 to 76.7)47.0 (11.8 to 94.0)68.5 (28.8 to 198)
PrimaryEfficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_Cmax

The efficacy of DZD was evaluated by measuring the change in mycobacterial load over time on treatment as quantified by TTP (Time to positive) in BD MGIT960® liquid culture described by non linear mixed effects methodology. A population PK model was developed using NONMEM version 7.4.1. DZD PK is well-described by a two-compartment model with first-order absorption, first-order elimination and a proportional residual error. The final model included allometric scaling based on FFM.

Time frame:
Week 0 - Week 16
Reported as:
Median · mg/L
Efficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_Cmax
mg/LArm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)
Efficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_CmaxNA (NA to NA)3.78 (2.92 to 4.45)7.72 (5.78 to 13.9)13.7 (9.56 to 19.7)9.16 (7.56 to 13.4)
PrimaryEfficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_Cmin

The efficacy of DZD was evaluated by measuring the change in mycobacterial load over time on treatment as quantified by TTP (Time to positive) in BD MGIT960® liquid culture described by non linear mixed effects methodology. A population PK model was developed using NONMEM version 7.4.1. DZD PK is well-described by a two-compartment model with first-order absorption, first-order elimination and a proportional residual error. The final model included allometric scaling based on FFM.

Time frame:
Week 0 - Week 16
Reported as:
Median · mg/L
Efficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_Cmin
mg/LArm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)
Efficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_CminNA (NA to NA)0.00296 (0.000437 to 0.459)0.00948 (0.000439 to 0.810)0.00240 (0.000215 to 0.291)0.00400 (0.000157 to 0.564)
SecondaryEfficacy Outcome: BD MGIT960® Liquid Media Culture Results

Summary of Changes in Mycobacterial Load Over Time on Treatment as Quantified by Time to Positivity in BD MGIT960® Liquid Media - Intent to Treat Population Sputum samples were collected for BD MGIT960® Liquid Media culture at all time points during the treatment and follow-up phases, and this table shows culture results, which are reported as: Positive, Negative, Contaminated, Missing. Note: Contaminated cultures are shown as contaminated for the purpose of the overall result but are counted as missing for calculating summary statistics. The data recorded as 'Positive for MTB Complex with Contamination' are included as 'Positive' for MGIT result. However, the data from mean and median calculations for TTP (Time to positive) due to contamination.

Time frame:
Week 0 - Week 16
Reported as:
Count of participants · Participants
Efficacy Outcome: BD MGIT960® Liquid Media Culture Results
ParticipantsArm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)
Week 0 — Positive1515151615
Week 0 — Negative00000
Week 0 — Contaminated00000
Week 0 — Missing00000
Week 1 — Positive1514151515
Week 1 — Negative01010
Week 1 — Contaminated00000
Week 1 — Missing00000
Week 2 — Positive1514141615
Week 2 — Negative01100
Week 2 — Contaminated00000
Week 2 — Missing00000
Week 3 — Positive1513121515
Week 3 — Negative02100
Week 3 — Contaminated00010
Week 3 — Missing00200
Week 4 — Positive1313131412
Week 4 — Negative22123
Week 4 — Contaminated00000
Week 4 — Missing00100
Week 5 — Positive1412111312
Week 5 — Negative13233
Week 5 — Contaminated00000
Week 5 — Missing00200
Week 6 — Positive99121012
Week 6 — Negative56263
Week 6 — Contaminated10000
Week 6 — Missing00100
Week 7 — Positive98588
Week 7 — Negative67987
Week 7 — Contaminated00000
Week 7 — Missing00100
Week 8 — Positive66527
Week 8 — Negative999137
Week 8 — Contaminated00011
Week 8 — Missing00100
Week 9 — Positive54332
Week 9 — Negative1011111311
Week 9 — Contaminated00001
Week 9 — Missing00101
Week 10 — Positive43133
Week 10 — Negative1012121311
Week 10 — Contaminated10101
Week 10 — Missing00100
Week 11 — Positive32112
Week 11 — Negative1112131413
Week 11 — Contaminated11010
Week 11 — Missing00100
Week 12 — Positive20002
Week 12 — Negative1215141613
Week 12 — Contaminated10000
Week 12 — Missing00100
Week 13 — Positive00003
Week 13 — Negative1515141512
Week 13 — Contaminated00010
Week 13 — Missing00100
Week 14 — Positive10002
Week 14 — Negative1315121411
Week 14 — Contaminated10222
Week 14 — Missing00100
Week 15 — Positive10001
Week 15 — Negative1415131614
Week 15 — Contaminated00100
Week 15 — Missing00100
Week 16 — Positive00001
Week 16 — Negative1415141614
Week 16 — Contaminated10000
Week 16 — Missing00100
SecondaryEfficacy Outcome: Changes in Mycobacterial Load Over Time on Treatment as Quantified by Time to Positivity in BD MGIT960® Liquid Media

The efficacy of DZD was evaluated by measuring the change in mycobacterial load over time on treatment as quantified by time to positivity (TTP) in BD MGIT 960® liquid culture described by nonlinear mixed-effects methodology. Sputum samples were collected for BD MGIT960® Liquid Media culture at all time points during the treatment and follow-up phases, and this table shows TTP results.

Time frame:
Week 0 - Week 16
Reported as:
Mean · days
Efficacy Outcome: Changes in Mycobacterial Load Over Time on Treatment as Quantified by Time to Positivity in BD MGIT960® Liquid Media
daysArm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)
Week 05.6 ± 2.26.5 ± 4.17.2 ± 5.78.0 ± 9.05.9 ± 2.2
Week 110.9 ± 3.213.0 ± 8.910.1 ± 3.811.1 ± 8.89.6 ± 3.3
Week 213.3 ± 4.316.9 ± 9.915.4 ± 8.613.7 ± 7.812.2 ± 3.7
Week 316.6 ± 6.518.0 ± 11.816.0 ± 8.414.2 ± 6.415.7 ± 8.2
Week 419.1 ± 10.418.3 ± 10.318.7 ± 8.121.2 ± 10.119.8 ± 12.1
Week 523.6 ± 9.224.4 ± 11.023.3 ± 10.125.3 ± 10.423.8 ± 10.8
Week 627.3 ± 11.929.7 ± 11.42.74 ± 8.427.9 ± 12.126.9 ± 10.3
Week 730.8 ± 11.731.6 ± 10.935.1 ± 9.733.6 ± 10.930.9 ± 12.5
Week 833.3 ± 12.036.6 ± 8.936.3 ± 9.739.4 ± 7.533.2 ± 11.1
Week 935.8 ± 10.337.7 ± 9.738.0 ± 8.337.0 ± 10.938.8 ± 7.8
Week 1036.4 ± 10.137.8 ± 9.140.5 ± 5.439.3 ± 7.339.7 ± 5.5
Week 1136.6 ± 11.540.1 ± 5.240.9 ± 4.341.4 ± 2.438.5 ± 9.4
Week 1238.5 ± 9.342.0 ± 042.0 ± 042.0 ± 040.0 ± 6.1
Week 1342.0 ± 042.0 ± 042.0 ± 042.0 ± 039.2 ± 7.3
Week 1439.9 ± 8.042.0 ± 042.0 ± 042.0 ± 039.4 ± 7.8
Week 1539.7 ± 8.942.0 ± 042.0 ± 042.0 ± 040.0 ± 7.8
Week 1642.0 ± 042.0 ± 042.0 ± 042.0 ± 040.0 ± 7.7
SecondaryEfficacy Outcome: Loewenstein-Jensen Solid Media Culture Results

Summary of Changes in Mycobacterial Load Over Time on Treatment as Quantified by Time to Culture Conversion in Loewenstein-Jensen Solid Media - Intent-to-Treat Population Sputum samples were collected for Loewenstein-Jensen Solid Media culture at at Week 0, Week 8, Week 12, Week 6 during the treatment and follow-up phases, and this table shows culture results, which are reported as: Positive, Negative, Contaminated, Missing.

Time frame:
Week 0 - Week 16
Reported as:
Count of participants · Participants
Efficacy Outcome: Loewenstein-Jensen Solid Media Culture Results
ParticipantsArm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)
Week 0 — Positive1415151615
Week 0 — Negative10000
Week 0 — Contaminated00000
Week 0 — Missing00000
Week 8 — Positive42313
Week 8 — Negative1112111512
Week 8 — Contaminated01000
Week 8 — Missing00100
Week 12 — Positive20001
Week 12 — Negative1315141614
Week 12 — Contaminated00000
Week 12 — Missing00100
Week 16 — Positive00001
Week 16 — Negative1415141614
Week 16 — Contaminated10000
Week 16 — Missing00100
SecondaryEfficacy Outcome: The Proportion Converted by Day Corresponding to End of Each Week

Culture conversion was defined as 2 negative cultures without an intervening positive culture. Time was measured as time on treatment until the first negative culture (up to Week 16 Visit). 'Converted by Week x' shows proportion converted by day corresponding to end of each week, e.g., Week 2 = Day 14.

Time frame:
Week 0 - Week 16
Reported as:
Number · percentage of participants
Efficacy Outcome: The Proportion Converted by Day Corresponding to End of Each Week
percentage of participantsArm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)
Week 000000
Week 206.76.700
Week 306.76.700
Week 46.76.713.86.213.3
Week 56.720.013.818.813.3
Week 633.340.021.037.513.3
Week 740.046.764.143.840.0
Week 860.073.364.175.046.7
Week 960.086.778.587.573.3
Week 1066.786.792.887.580.0
Week 1173.386.792.893.886.7
Week 1280.010010010086.7
Week 1393.310010010086.7
Week 1493.310010010086.7
Week 1593.310010010093.3
Week 1693.310010010093.3
SecondaryEfficacy Outcome: Time to Culture Conversion

Time to culture conversion was defined as 2 negative cultures without an intervening positive culture. Time was measured as time on treatment until the first negative culture (up to Week 16 Visit).

Time frame:
Week 0 - Week 16
Reported as:
Median · Days
Efficacy Outcome: Time to Culture Conversion
DaysArm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)
Efficacy Outcome: Time to Culture Conversion56.0 (42.0 to 84.0)56.0 (42.0 to 63.0)59.0 (49.0 to 63.0)56.0 (42.0 to 59.5)63.0 (49.0 to 70.0)
SecondaryEfficacy Outcome : Relapse or Reinfection

A participant was positive for relapse or reinfection if they converted to culture negative by Week 8 and had 2 consecutive positive cultures after Week 16 of randomization, without an intervening negative.

Time frame:
Week0 - Week52
Reported as:
Count of participants · Participants
Efficacy Outcome : Relapse or Reinfection
ParticipantsArm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)
Conversion by Week 8 and no positive culture past week 1291110125
Conversion by Week 8 and positive culture past week 1200002
Did not convert by Week 864548
Relapsed or reinfected00000
Death00000

Adverse events

Collected over From Week 0 to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm1(D0)0/15 (0%)0/15 (0%)8/15 (53.3%)
Arm2(D400)0/15 (0%)0/15 (0%)7/15 (46.7%)
Arm3(D800-OD)0/15 (0%)1/15 (6.7%)7/15 (46.7%)
Arm4(D1200)0/16 (0%)0/16 (0%)6/16 (37.5%)
Arm5(D800-BD)0/15 (0%)2/15 (13.3%)9/15 (60%)
Most frequent serious events
Most frequent serious events
EventArm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)
GastritisGastrointestinal disorders0/150/150/150/161/15
AnaemiaBlood and lymphatic system disorders0/150/150/150/161/15
Diabetic ketoacidosisMetabolism and nutrition disorders0/150/151/150/160/15
Most frequent other events
Showing 10 of 20
Most frequent other events
EventArm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)
NauseaGastrointestinal disorders2/150/153/152/164/15
VomitingGastrointestinal disorders2/150/151/152/163/15
AnemiaBlood and lymphatic system disorders0/150/151/150/162/15
TachycardiaCardiac disorders0/150/150/150/162/15
Electrocardiogram QT prolongedInvestigations2/152/152/151/161/15
Gamma glutamyl transferase increasedInvestigations0/151/150/150/162/15
HeadacheNervous system disorders0/150/151/151/162/15
TachypnoeaRespiratory, thoracic and mediastinal disorders0/150/152/150/160/15
PyrexiaGeneral disorders0/151/151/151/161/15
ConjunctivitisInfections and infestations0/150/151/150/161/15

Baseline characteristics

Intent-to-Treat Population and Safety Population

Age, Continuous
Age, Continuous(years)Arm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)Total
Mean35.6 ± 10.339.7 ± 9.035.1 ± 11.334.1 ± 7.133.3 ± 8.435.5 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Arm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)Total
Female2037416
Male13151291160
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)Total
Hispanic or Latino000000
Not Hispanic or Latino141514161574
Unknown or Not Reported101002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)Total
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American151515161576
White000000
More than one race000000
Unknown or Not Reported000000
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m2)Arm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)Total
Mean18.2 ± 1.818.8 ± 2.120.0 ± 3.820.2 ± 3.020.0 ± 3.519.5 ± 3.0
HIV status
HIV status(Participants)Arm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)Total
Negative131412131365
Positive2133211
GeneXpert CT results
GeneXpert CT results(Participants)Arm1(D0)Arm2(D400)Arm3(D800-OD)Arm4(D1200)Arm5(D800-BD)Total
< 16 ; high bacili (TB) load3333315
≥ 16 ; low bacili (TB) load121212131261
09

Study locations

5 sites
  • The Aurum Institute Tembisa Clinical Research Centre
    Tembisa, Gauteng 1632, South Africa
  • Clinical HIV Research Unit (CHRU) University of the Witwatersrand
    Johannesburg, 2092, South Africa
  • Ifakara Health Institute
    Bagamoyo, Tanzania
  • National Institute for Medical Research (NIMR-MMRC)
    Mbeya, Tanzania
  • Ki'bongoto Infectious Disease Hospital (KIDH) Kilimanjaro Clinical Research Institute (KCRI)
    Moshi, Tanzania
10

References and documents

Publications

  • Minja LT, van der Feltz I, Manyama C, Mpagama S, Mhimbira F, Norena I, Sebe M, Rassool M, Wallis RS, Ntinginya N, Liyoyo A, Mbeya B, Wagnerberger L, Zumba T, Peter DD, Makkan H, Sloan DJ, Brake LT, Schildkraut JA, Aarnoutse R, McHugh TD, Wildner L, Boeree MJ, Geiter L, Cho YL, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N; PanACEA consortium. Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial. Lancet Infect Dis. 2025 Nov;25(11):1219-1229. doi: 10.1016/S1473-3099(25)00289-0. Epub 2025 Jul 8. PubMed 40645198 ↗
  • Dierig A, Hoelscher M, Schultz S, Hoffmann L, Jarchow-MacDonald A, Svensson EM, Te Brake L, Aarnoutse R, Boeree M, McHugh TD, Wildner LM, Gong X, Phillips P, Minja LT, Ntinginya N, Mpagama S, Liyoyo A, Wallis RS, Sebe M, Mhimbira FA, Mbeya B, Rassool M, Geiter L, Cho YL, Heinrich N. A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis. Trials. 2023 Jun 6;24(1):382. doi: 10.1186/s13063-023-07354-5. PubMed 37280643 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Deidentified individual patient data, that underlie the results in published article(s) based on data from the trial which including text, tables, figures will be presented to various stakeholders. This reported will be presented to various stakeholder during various forums or meetings. First esults will be disclosed to participants, staff and our site Community Advisory Board. Thereafter we would invite several stakeholders from the community or visit their establishments to review study results. Simultaneously, the studying findings report will be sent to the various regulatory authorities, including the National Department of Health (NDoH). With NDoH and its divisions we will establish needs for further engagement and suggestions for policy or programmatic changes.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: PD will be provided 1 - 2 years after and up to 5 years after the publication of the article on the results of the trial

Access criteria: IPD access will be provided for analyses of related to the aims of research described in the protocol and for individual patient data meta-analyses to researchers who provide a methodologically sound proposal to yhlee@ligachembio.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jan 2023, 14 months.

Results were first posted in Oct 2024, 1 year 9 months after primary completion.

Of 43 phase 2 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 37. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2020
First posted
Sep 16, 2020
StartActual
Oct 28, 2021
Primary completionActual
Jan 4, 2023
CompletionActual
Sep 11, 2023
Results first posted
Oct 28, 2024
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04550832
Lead sponsor
LigaChem Biosciences, Inc.
Responsible party
Sponsor
First posted
Sep 16, 2020
Start date
Oct 28, 2021
Primary completion
Jan 4, 2023
Completion
Sep 11, 2023
Results posted
Oct 28, 2024
Last update
Sep 16, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delpazolid

Start the discussion